Publications by authors named "S Yoshihiro"
Article Synopsis
- This systematic review and meta-analysis assessed how enhanced rehabilitation after hospital discharge affects the quality of life (QOL) for survivors of critical care, following PRISMA guidelines and examining data from several major health databases until January 2024.
- The review included nine randomized controlled trials (RCTs) with 573 participants, finding that enhanced rehabilitation showed no significant improvement in physical QOL but did result in a higher mental QOL score (low-certainty evidence).
- Adverse events' impact was uncertain, with mixed reports from the studies; some had no adverse events, while others noted serious incidents, indicating very low-certainty evidence on this issue.
Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors.
Keita Kobayashi Shigeru Sakano Hiroaki Matsumoto Mitsutaka Yamamoto Masahiro Tsuchida Satoru Yoshihiro
Jpn J Clin Oncol
October 2024
Article Synopsis
- A study examined the effectiveness of avelumab and pembrolizumab, treatments for metastatic urothelial carcinoma post-chemotherapy, focusing on factors predicting patient outcomes.
- The research included 243 patients, analyzing characteristics and blood data to identify independent prognostic factors like performance status and specific blood markers.
- Findings indicate a new risk score utilizing platelet-to-lymphocyte ratio and lactate dehydrogenase levels could effectively predict overall survival after starting immune checkpoint inhibitors, outperforming existing models.
Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.
Keita Kobayashi Hiroaki Matsumoto Shigeru Sakano Mitsutaka Yamamoto Masahiro Tsuchida Satoru Yoshihiro
Clin Genitourin Cancer
December 2024
Article Synopsis
- A study examined the effectiveness of avelumab maintenance therapy compared to pembrolizumab in patients with metastatic and unresectable urothelial carcinoma after 4 cycles of chemotherapy without disease progression.
- Data from 243 patients treated between January 2017 and December 2022 was analyzed, with a focus on oncological outcomes and adverse events using a method called propensity score matching.
- The findings indicated that both avelumab and pembrolizumab had similar progression-free survival rates, but avelumab required a lower rate of high-dose glucocorticoid treatment.
True Effect of Fludrocortisone for Septic Shock: Baseline Risk and Transitivity Concerns.
Am J Respir Crit Care Med
November 2024
Objectives: To determine optional therapeutic strategies by comparing monotherapies and combination therapies to reduce RBC transfusion requirement for patients in the ICU.
Data Sources: MEDLINE, CENTRAL, and Embase were searched for studies published from database inception until July 2023.
Data Extraction: We included randomized controlled trials comparing erythropoiesis-stimulating agents (Epo), iron, combination therapy with iron and Epo, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vitamin D 3 (VD3), and placebo/no treatment.